Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Theravance Biopharma, Inc.TBPH · Entity 5037 | SVP, Research | August 20, 2019 | August 22, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Theravance Biopharma, Inc.
Report date August 20, 2019 · Filed August 22, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 259,900 |
Reported balance
After 2019-08-20 transaction · row 1
1 source rowRow 1 · 2019-08-20 · Tax withholding · Disposed 2,272 · Balance 259,900 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 20, 2019 Filed Aug 22, 2019 18:01 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 2,272 | $21.51 | $48,870.72 |
DisclosureSEC source: 0001179110-19-009788 · edgar.xml · nonDerivative · entry 1 HEGDE SHARATHCHANDRA S · CIK 0001668696 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,900 Read SEC document |
| May 20, 2019 Filed May 22, 2019 18:07 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 2,272 | $19.84 | $45,076.48 |
DisclosureSEC source: 0001179110-19-006522 · edgar.xml · nonDerivative · entry 1 HEGDE SHARATHCHANDRA S · CIK 0001668696 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,172 Read SEC document |
| March 05, 2019 Filed Mar 6, 2019 19:20 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 5,690 | $24.50 | $139,405.00 |
DisclosureSEC source: 0001179110-19-003477 · edgar.xml · nonDerivative · entry 2 HEGDE SHARATHCHANDRA S · CIK 0001668696 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,444 F2 · price: This transaction was executed in multiple trades at prices from $24.4953 to $24.515. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 19:20 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 3,343 | $25.06 | $83,763.55 |
DisclosureSEC source: 0001179110-19-003477 · edgar.xml · nonDerivative · entry 1 HEGDE SHARATHCHANDRA S · CIK 0001668696 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,134 F1 · price: This transaction was executed in multiple trades at prices from $25.00 to $25.27. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 18:15 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 3,770 | $27.00 | $101,790.00 |
DisclosureSEC source: 0001179110-19-002413 · edgar.xml · nonDerivative · entry 1 HEGDE SHARATHCHANDRA S · CIK 0001668696 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,477 Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 17:45 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 47,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-001561 · edgar.xml · nonDerivative · entry 2 HEGDE SHARATHCHANDRA S · CIK 0001668696 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,247 F1 · shares: On March 15, 2016, the reporting person was granted a performance stock award that vests based on the achievement of certain performance conditions over a five-year timeframe from 2016 through December 31, 2020 and continued employment. On February 5, 2019, the performance conditions applicable to 47,250 shares were achieved and such shares will vest on February 20, 2020, subject to the reporting person's continued service. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 17:45 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-001561 · edgar.xml · nonDerivative · entry 1 HEGDE SHARATHCHANDRA S · CIK 0001668696 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,997 Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 17:44 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 4,063 | $24.79 | $100,721.77 |
DisclosureSEC source: 0001179110-18-013107 · edgar.xml · nonDerivative · entry 1 HEGDE SHARATHCHANDRA S · CIK 0001668696 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,997 Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 19:33 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 5,198 | $26.95 | $140,086.10 |
DisclosureSEC source: 0001179110-18-010819 · edgar.xml · nonDerivative · entry 1 HEGDE SHARATHCHANDRA S · CIK 0001668696 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,060 Read SEC document |
| May 20, 2018 Filed May 22, 2018 19:01 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 19,103 | $24.31 | $464,393.93 |
DisclosureSEC source: 0001179110-18-007372 · edgar.xml · nonDerivative · entry 1 HEGDE SHARATHCHANDRA S · CIK 0001668696 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,258 Read SEC document |
| May 14, 2018 Filed May 16, 2018 19:03 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 33,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-006936 · edgar.xml · nonDerivative · entry 1 HEGDE SHARATHCHANDRA S · CIK 0001668696 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,361 F1 · shares: On March 15, 2016, the reporting person was granted a performance stock award that vests based on the achievement of certain performance conditions over a five-year timeframe from 2016 through December 31, 2020 and continued employment. On May 14, 2018, the performance conditions applicable to 33,750 shares were achieved and such shares will vest on May 20, 2018. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 17:39 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 4,349 | $29.09 | $126,512.41 |
DisclosureSEC source: 0001179110-18-002608 · edgar.xml · nonDerivative · entry 1 HEGDE SHARATHCHANDRA S · CIK 0001668696 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,611 Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 18:20 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002123 · edgar.xml · nonDerivative · entry 1 HEGDE SHARATHCHANDRA S · CIK 0001668696 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,960 Read SEC document |
| November 20, 2017 Filed Nov 22, 2017 16:38 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 5,177 | $28.58 | $147,958.66 |
DisclosureSEC source: 0001179110-17-014563 · edgar.xml · nonDerivative · entry 1 HEGDE SHARATHCHANDRA S · CIK 0001668696 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,960 Read SEC document |
| August 20, 2017 Filed Aug 22, 2017 18:28 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 5,176 | $27.40 | $141,822.40 |
DisclosureSEC source: 0001179110-17-011748 · edgar.xml · nonDerivative · entry 1 HEGDE SHARATHCHANDRA S · CIK 0001668696 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,137 Read SEC document |
| May 20, 2017 Filed May 23, 2017 19:59 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 5,177 | $36.83 | $190,668.91 |
DisclosureSEC source: 0001179110-17-007878 · edgar.xml · nonDerivative · entry 1 HEGDE SHARATHCHANDRA S · CIK 0001668696 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,313 Read SEC document |
| February 20, 2017 Filed Feb 22, 2017 19:06 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 10,138 | $33.78 | $342,461.64 |
DisclosureSEC source: 0001179110-17-002990 · edgar.xml · nonDerivative · entry 1 HEGDE SHARATHCHANDRA S · CIK 0001668696 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,490 Read SEC document |
| February 06, 2017 Filed Feb 8, 2017 19:07 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-001999 · edgar.xml · nonDerivative · entry 1 HEGDE SHARATHCHANDRA S · CIK 0001668696 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,628 Read SEC document |
| November 20, 2016 Filed Nov 22, 2016 18:03 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 1,845 | $31.96 | $58,966.20 |
DisclosureSEC source: 0001179110-16-031977 · edgar.xml · nonDerivative · entry 1 HEGDE SHARATHCHANDRA S · CIK 0001668696 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,628 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.